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Children admitted to the pediatric intensive care unit after cardiovascular surgery usually
require treatment with antibiotics due to suspicion of infection. The aim of this study was to
assess the effectiveness of procalcitonin in decreasing the duration of antibiotic treatment in
children after cardiovascular surgery.
Methods
Prospective, interventional study carried out in a pediatric intensive care unit. Included
patients under 18 years old admitted after cardiopulmonary bypass. Two groups were com-
pared, depending on the implementation of the PCT-guided protocol to stop or de-escalate
the antibiotic treatment (Group 1, 2011–2013 and group 2, 2014–2018). This new protocol
was based on the decrease of the PCT value by 20% or 50% with respect to the maximum
value of PCT. Primary endpoints were mortality, stewardship indication, duration of antibi-
otic treatment, and antibiotic-free days.
Results
886 patients were recruited. There were 226 suspicions of infection (25.5%), and they were
confirmed in 38 cases (16.8%). The global rate of infections was 4.3%. 102 patients
received broad-spectrum antibiotic (4.7±1.7 days in group 1, 3.9±1 days in group 2 with p =
0.160). The rate of de-escalation was higher in group 2 (30/62, 48.4%) than in group 1 (24/
92, 26.1%) with p = 0.004. A reduction of 1.1 days of antibiotic treatment (group 1, 7.7±2.2







Citation: Bobillo-Perez S, Sole-Ribalta A, Balaguer
M, Esteban E, Girona-Alarcon M, Hernandez-
Platero L, et al. (2019) Procalcitonin to stop
antibiotics after cardiovascular surgery in a
pediatric intensive care unit—The PROSACAB
study. PLoS ONE 14(9): e0220686. https://doi.org/
10.1371/journal.pone.0220686
Editor: Martina Crivellari, Vita Salute University of
Milan, ITALY
Received: May 17, 2019
Accepted: July 22, 2019
Published: September 18, 2019
Copyright: © 2019 Bobillo-Perez et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The minimal
anonymized data set for this study has been
deposited to the BioStudies database and can be
accessed via https://www.ebi.ac.uk/biostudies/
studies/S-BSST279.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
and group 2, 6.7±2.2, with p = 0.005) and 2 more antibiotic free-days free in PICU in group 2
were observed (p = 0.001), without adverse outcomes.
Conclusions
Procalcitonin-guided protocol for stewardship after cardiac surgery seems to be safe and
useful to decrease the antibiotic exposure. This protocol could help to reduce the duration of
broad-spectrum antibiotics and the duration of antibiotics in total, without developing compli-
cations or adverse effects.
Introduction
The prescription and duration of antibiotic treatment have been carefully reviewed in recent
years because of the growing incidence of infections and new emergent multidrug-resistant
bacteria. Antimicrobial resistance is responsible for 35,000 deaths per year in Spain and
700,000 worldwide, and a progressive rise is foreseen, until reaching 10 million in 2050. In
addition, healthcare-associated infections (HAI) affect 4.5 million patients worldwide, prolong
length of stay (LOS) by 16 million days, and are responsible for 37,000 deaths each year in
Europe. The annual cost of antimicrobial resistance and HAI in the European Union is around
1.5 and 7 billion euros, respectively. The maximum exponents of this situation are the inten-
sive care units, where vulnerable critically ill patients require invasive devices and receive
more antibiotics [1–3]. The extension of antimicrobial resistances, especially in the gram-nega-
tive bacilli, concerns all the medical community.
Post cardiovascular surgery (CVS) patients are a population that usually requires antibiotic
treatment and HAI is a frequent complication. The incidence of HAI in these patients is about
the 10–20% but interinstitutional variations exist [4–6]. Patients receive antibiotic prophylaxis
before and after CVS. This prophylaxis is frequently changed by empirical antibiotic treatment
when the patient develops signs and symptoms that are common for infection and systemic
inflammatory response being difficult to distinguish both entities, especially in more compli-
cated patients. The systemic inflammatory response is secondary to the released storm of cyto-
kines after the extracorporeal circulation during CVS. This antibiotic treatment is usually
indicated when patients have fever, hypotension, alteration of C-reactive protein, although
most of the time, these symptoms are secondary to inflammation and not to infection. Once
started, the duration of antibiotic treatment is mostly established by the clinical evolution and
depending on the isolated microorganism in cultures. Recently, some biomarkers such as pro-
calcitonin (PCT) have been added to the antibiotic treatment algorithms in order to give an
objective parameter of bacterial infection and of the antibiotic response [7]. PCT is a well-
known biomarker, mainly used for diagnosing bacterial infection in different settings, such as
intensive care units. Its determination has been demonstrated to be helpful to differentiate
post-surgery infection from systemic inflammatory response in adults and children [8–12],
but also for guiding the antibiotic duration and improving antibiotic stewardship, especially in
adults [13–18]. Studies regarding PCT-guided stewardship in children are limited.
Patients affected by complex heart disease may need more than one complex surgery in
their childhood, with a long LOS in hospital. So limiting exposure to broad-spectrum antibiot-
ics should be the goal of physicians in order to help in reducing multidrug resistance, to
improve antibiotic strategies, to avoid secondary antibiotic effects, and to decrease costs.
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The main aim of this study was to determine the effectiveness of PCT in decreasing the
duration of antibiotic treatment in children after CVS. Secondary objectives were to determine
if this approach based on a PCT-guided protocol helped to decrease pediatric intensive care
(PICU) without increasing complications.
Materials and methods
Prospective, unicenter, interventional study, conducted in a PICU. Inclusion criteria were chil-
dren under 18 years of age who were admitted after CVS to the PICU of a third level hospital.
Excluded criteria were newborn who were admitted to the neonatal intensive care unit after
CVS (due to the different antibiotic policy of that unit), patients with rheumatologic disease
(PCT value may increase in rheumatic outbreaks) or immunodeficiency (these patients receive
individualised antibiotherapy), and patients with suspicion of community infections.
Two different groups of patients were compared over time. Group 1 included patients
recruited from 2011 to 2013 and group 2 from 2014 to 2018. The difference between both
groups was the implementation in group 2 of the PCT-guided protocol to stop or provide
stewardship in the antibiotic treatment. Primary endpoints were death in the PICU, steward-
ship indication, duration of antibiotic treatment, and antibiotic-free days. Secondary end-
points were reinfections, relapses, and the LOS in PICU.
Antibiotic policy
After CVS all patients received antibiotic (cefazoline) as prophylaxis until the withdrawal of
mediastinal drainage. Since 2010 the infection diagnosis and subsequent antibiotic treatment
had been based on clinical (fever, bad general condition) and analytical (leukocyte count, C
reactive protein, and PCT values [9]) data. The antibiotic duration was determined by the
medical staff criteria, according to clinical evolution, culture results, and type of infection [19–
21]. The stewardship to a narrow-spectrum antibiotic was recommended according to the lab-
oratory sensitivity results. In 2014, a new antibiotic policy algorithm was defined for patients
after CVS patients, based on an algorithm guided by PCT (Fig 1).
In relation to the suspension of the antibiotic, the new protocol added as a criterion the
decrease in PCT values of more than 50% of the initial value or the decrease of the PCT value
below 0.5 ng/mL. No other significant changes were introduced in the antibiotic policy algo-
rithm. Nevertheless, the final decision is at the discretion of the attending physician.
For the study patients were diagnosed with nosocomial infection based on the Centre for
Disease Control and Prevention criteria [22]. Sepsis diagnosis is defined according to the inter-
national definition of paediatric sepsis revised in 2012 [23]. Reinfection is considered as the
development of a new infection after the first infection is solved. Relapse is defined as the
development of an infection by the same bacteria that caused the first infection in the first two
weeks after the previous one. De-escalation is considered as the change of the antibiotic to one
of minor or narrow-spectrum. In group 1, the analysis was carried out by the researcher who,
considering the medical evolution and results of the cultures, determined whether the de-esca-
lation/stop would have been indicated. The indication of de-escalation/stop in group 2 was
determined by the algorithm of the new protocol (Fig 1). The de-escalation indication includes
those patients in which it is correctly applied and those in which, when indicated, it is not per-
formed. De-escalation is not applicable when the initial therapy was correct for the confirmed
bacterial infection or when the antibiotic was stopped early in the absence of signs of infection.
The number of days of antibiotics includes prophylaxis and treatment. The antibiotic-free
days are the difference between the duration of the antibiotics (including prophylaxis) and the
LOS in PICU and in hospital.
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PCT values were determined by LumiTest PCT immunoluminometric assay (ATOM SA;
Brahms Diagnostica, Middletown, VA), which uses two monoclonal antibodies and requires
20 μL of serum or plasma. Serial PCT values were determined daily during the 3 first days after
CVS and if a suspicion of infection existed, daily until the resolution of the process.
Baseline demographic data were recorded and included: type of congenital heart disease,
complexity of surgery (Aristotle score [24]), surgery times (time of extracorporeal circulation,
aortic cross clamp and deep hypothermic circulatory arrest), and Pediatric Risk Mortality
Score (PRISM III). Haemodynamic and respiratory support in the first days after surgery were
also analysed, both in absolute numbers, assessing the need for inotropes at 24 hours from sur-
gery (different from milrinone, which per protocol is administered in the first hours after
extracorporeal circulation) and intubation upon admission, such as the vasoactive-inotropic
score (VIS) [25] and the hours of mechanical ventilation. Infection data included: device-
related nosocomial infection (ventilator associated pneumonia, central line associated blood
stream infection, catheter associated urinary tract infection), a diagnosis of sepsis, antibiotic
treatment stewardship and duration, and antibiotic-free days. LOS in the PICU and in the hos-
pital were recorded. Reinfection and relapse were considered as adverse outcomes.
SPSS 22.0 for Windows was used for statistical analysis. Qualitative variables were expressed
as frequencies and percentages and compared using Pearson chi-square test. Quantitative
Fig 1. Algorithm of the procalcitonin-guided antimicrobial stewardship protocol. PCT: Procalcitonin.
https://doi.org/10.1371/journal.pone.0220686.g001
Procalcitonin to stop antibiotics after cardiovascular surgery in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0220686 September 18, 2019 4 / 14
variables were expressed by median and interquartile rang (IQR) and compared using Mann-
Whitney test or mean and standard deviation depending on the distribution of the sample and
compared using t-student test. Kruskall-Wallis test was also used for comparing various quali-
tative variables and a quantitative variable. In order to analyze the possibility of negative effects
(increase in mortality or LOS) after the introduction of the new protocol, a multivariate analy-
sis was proposed. A backward stepwise logistic regression was performed and results were
expressed as Odds Ratio (OR) and confidence interval (CI95%). A p-value < 0.05 was consid-
ered significant.
The study was conducted in accordance with the Helsinki Declaration recommendations
and approved by the local Ethical Assistance Committee (CEIm Fundacion Sant Joan de Deu,
Barcelona) and the institutional review board with a waiver of individual informed consent.
Results
A total of 886 patients were recruited, 371 in group 1 (41.8%, pre-implementation the PCT
guided protocol) and 515 in group 2 (58.2%, post-implementation). The median age was 1.5
years (IQR 0.5–6.5) and 476 were males (53.7%). Two-hundred and seventy-four patients
(30.9%) had previously undergone cardiac surgery and 142 patients (16%) had an underlying
disease, 57 of them Down syndrome (40.1%). The main type of congenital heart disease was
the left-to-right shunt heart defect, with 410 patients (46.3%); 282 patients (31.8%) had a cya-
notic cardiac defect, 163 (18.4%) obstructive CHD, and, finally, 31 patients (3.5%) had other
CHDs. The ventricular septal defects and the tetralogy of Fallot were the two most frequent
CHDs with 152 (17.16%) and 133 patients (15%), respectively. Aristotle score was 2 in 410
patients (46.3%) and was higher than 2 in 257 patients (29%). The median PRISM III was 3
points (IQR 2–6). There were no statistically significant differences between the two groups
according to any clinical data on previous surgery. All data are summarized in Table 1.
There were no differences according to need for haemodynamic and respiratory support,
renal replacement therapy, or ECMO. Patients in group 2 needed more haemodynamic sup-
port in the first 24 hours but not in the 48 hours after surgery. Twenty-five (2.8%) needed an
urgent re-intervention, in 5 cases due to severe bleeding. The median number of days of anti-
biotic was 2 (IQR 2–4). The prescription of antibiotics was greater in group 1 (113 patients,
30.5%) than in group 2 (114 patients, 22.1%) with p = 0.004.
There were 226 patients with suspicion of infection (25.6%), 114 (30.7%) in group 1 and
112 (21.7%) in group 2 (p = 0.002). The infection was confirmed in 38 patients (38/226, 16.8%)
and the global rate of infection was 38/886 (4.3%). In patients with suspicion of infection, the
confirmation of it was greater in group 1, but without statistically significant differences
(group 1, 22 patients, 19.3% vs group 2, 16 patients, 14.3%, p = 0.314). The evolution of PCT
over time according to the confirmation of infection in patients with suspicion of infection is
represented in Fig 2.
The median value for PCT at the beginning of the empiric antibiotic treatment was 5.9 ng/
mL (IQR 2.6–13.6), being higher in those in whom the infection was finally confirmed (6.7 ng/
mL, IQR 4–38.6), vs 5.05 (IQR 2–9.9) than those without confirmed infection (p = 0.03)). The
median value of PCT at the stewardship (stop or de-escalation) was 0.53ng/mL (IQR 0.2–
2.77). The most frequent infections were ventilator associated pneumonia (30, 13.3%), fol-
lowed by sepsis (6, 2.7%); Culture-negative sepsis were more frequent in group 2 with statisti-
cally significant differences (p = 0.036). Table 2 summarizes the differences between the two
groups and each type of infection. Gram-negative bacteria were the most frequent type of iso-
lated microorganism (27 patients), followed by gram-positive bacteria (11 patients). Fig 3 rep-
resents the evolution of PCT in patients infected by each type of microorganism. Patients
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Table 1. General summary for the sample of the demographic data, surgical characteristics, and postoperative support in the paediatric intensive care unit.
Variables TOTAL (n = 886) GROUP 1 (n = 371) GROUP 2 (n = 515) p-value
2011–2013 2014–2018
Demographic and surgery
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infected by gram-positive bacteria tended to have higher PCT values but no statistically signifi-
cant differences were detected (at 24, 48 and 72 hours, p = 0.530; 0.847 and 0.505 respectively).
The main isolated bacteria were Pseudomona aeruginosa and Enterobacter cloacae, with 5
patients each. There were 4 positive cultures for Klebsiella pneumoniae and 4 for Serratia mar-
cescens. Three patients were infected by Candida spp. No multidrug-resistant bacteria were
isolated. There were no statistically significant differences in the use of broad-spectrum antibi-
otics between the two groups. All data are summarized in Table 2.
The de-escalation would have been indicated in 154 patients, 92 in group 1 (81.4%) and 62
in group 2 (54.8%), with p<0.001, but it was only done in 24 patients in group 1 (24/92,
26.1%) and in 30 patients in group 2 (30/62, 48.4%). Differences were statistically significant
with a higher rate of de-escalation in group 2 than in group 1 (p = 0.004). There were no differ-
ences regarding the de-escalation to an antibiotic of minor spectrum: 24/114 (21.1%) in group
Table 1. (Continued)
Variables TOTAL (n = 886) GROUP 1 (n = 371) GROUP 2 (n = 515) p-value
2011–2013 2014–2018







Qualitative values expressed by frequencies (Percentages) and compared with Pearson’ Chi-square test. Quantitative values expressed by median (INTERQUARTIL
RANGE).
Mann-Whitney test.
�Need for inotropic support in PICU different from milrinone.
�� Including urgent cardiac catheterization or cardiovascular surgery.
AB: Antibiotic; EC: Extracorporeal circulation; CHD: Congenital heart disease; DHCA: Deep hypothermic circulatory arrest; ECMO: Extracorporeal membrane
oxygenation therapy; LOS: Length of stay; min: minutes; MV: Mechanical ventilation; PICU: Paediatric Intensive Care Unit; PRISM: Paediatric risk mortality score;
RRT: Renal replacement therapy; VIS: vasoactive-inotropic score.
https://doi.org/10.1371/journal.pone.0220686.t001
Fig 2. Graphic of the evolution of procalcitonin (PCT, ng/mL) over time according to the confirmation of infection in
patients with suspicion of infection (all together). Mann-Whitney U test.
https://doi.org/10.1371/journal.pone.0220686.g002
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1 vs 30/112 (26.7%) in group 2 with p = 0.260. However, the de-escalation was not applicable
in more patients in group 2 (51/114, 44.7%) than in group 1, (22/113, 19.5%) with p<0.001.
On the other hand there were fewer de-escalations or early cessations of the antibiotic in
group 2 (group 1, 68/113, 60.2% vs group 2, 32/114, 28.1%, with p<0.001). The de-escalation
was performed before in group 2 but statistically significant differences were not demonstrated
(group 1, 4 days until de-escalation (IQR 3–5) vs group 2, 3 days (IQR 3–5) with p = 0.173). In
those patients who received broad-spectrum antibiotics (n = 104), there were differences
according to the number of days of broad-spectrum antibiotic treatment before de-escalation
Table 2. Summary of the patients with suspicion of infection.
Variables TOTAL (n = 226) GROUP 1 (n = 114) GROUP 2 (n = 112) p-value
2011–2013 2014–2018
Broad-spectrum AB–n, % 102, 45.1% 51, 44.7% 51, 45.5% 0.282
Confirmed bacterial infection–n, % 38, 16.8% 22, 19.3% 16, 14.3% 0.314
Infection site–n, %
VAP 30, 13.3% 17, 14.9% 13, 11.6% 0.464
CLABSI 6, 2.7% 4, 3.5% 2, 1.8% 0.420
CAUTI 1, 0.4% 0, 0% 1, 0.9% 0.312
Wound 1, 13.2% 1, 0.9% 0, 0% 0.321
Probable infection:
Culture-negative sepsis–n, %
30, 13.3% 7, 6.1% 23, 20.5% 0.036
AB de-escalation–n, %
Yes 54, 23.8% 24, 21.1% 30, 26.7% 0.260
Not applicable 73, 32.2% 22, 19.5% 51, 44.7% <0.001
No stop/No de-escalation 100, 44.1% 68, 60.2% 32, 28.1% <0.001
Days to stewardship
Mean± SD 4±1.4 4.47±1.7 3.7±1.2 0.100
Median (IQR) 4 (3–5) 4 (3–5) 3 (3–5) 0.173
Total days of AB�
Mean± SD 7.21±0.16 7.7±2.2 6.7±2.2 0.005
Median (IQR) 7 (6–8) 7 (6–9) 7 (5–8) 0.003
AB-free days in PICU
Mean± SD 2.33±11.5 0.17±6.8 4.5±14.4 0.005
Median (IQR) -1 (-3-2) -2 (-3-1) 0 (-2-4) 0.001
AB-free-days in total
Mean± SD 9.7±18.6 6.8±11.9 12.5±23.2 0.023
Median (IQR) 4 (1–9) 3 (0–8) 5 (1–13) 0.015
Reinfection–n, % 24 (10.6%) 10 (8.8%) 14 (12.5%) 0.375
Relapse–n, % 0 0 0
LOS in PICU (days)
Mean± SD 9.5±11.9 7.8±8 11.1±14.7 0.037
Median (IQR) 6 (3–9) 6 (3–9) 6 (4–12.8) 0.179
Exitus in PICU–n, % 7 (3.1%) 5 (4.4%) 2 (1.8%) 0.259
Qualitative values expressed by frequencies (Percentages) and compared with Pearson’ Chi-square test. Quantitative values expressed by mean (STANDARD
DEVIATION, SD), compared with student-t test, and also expressed by median (INTERQUARTIL RANGE, IQR) and compared with Mann-Whitney Test.
�The duration of antibiotic includes the days of prophylaxis and treatment.
AB: Antibiotic; CAUTI: catheter-associated urinary tract infections; CLABSI: central-line associated bloodstream infections; LOS: Length of stay; min: minutes; PICU:
Paediatric Intensive Care Unit; VAP: ventilator-associated pneumonia.
https://doi.org/10.1371/journal.pone.0220686.t002
Procalcitonin to stop antibiotics after cardiovascular surgery in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0220686 September 18, 2019 8 / 14
of the treatment, with a reduction of 0.7 days of broad spectrum antibiotic (group 1, 4.7±1.7
days vs group 2, 3.9±1 days with p = 0.160).
There were statistically significant differences between the two groups according to the
duration of antibiotic: the median number days of antibiotics was 7 (IQR 6–9) in group 1 and
7 (IQR 5–8) in group 2, with p<0.001and a significant reduction of 1.1 days (mean in group 1,
7.7±2.3 and mean in group 2, 6.6±2.4, with p<0.005). The antibiotic-free days in PICU were
different in the two groups, with 2 more days free of antibiotics in PICU in group 2 than in
group 1 (p<0.005). According to the antibiotic-free days during hospitalization, there were
also 2 more days free of antibiotics in group 2, with p = 0.009. All data are summarized in
Table 2. In the overall sample (n = 886), no differences according to mortality in PICU were
observed (6 in group 1, 1.6%; and 5 in group 2, 1%; p = 0.391). Likewise, in suspected infected
patients (n = 227), no differences in mortality were detected (group 1, 5, 4.4% vs group 2, 2
patients, 1.8%, p = 0.245). One patient from the group 1 died due to an infectious disease with
shock: the bloodstream culture was positive for Staphylococcus epidermidis 24 hours after
surgery.
No differences were observed in the reinfection rate in the entire sample (group 1, 13/371
patients and 3.5%; group 2, 21/515 patients and 4.1%, p = 0.667). Relapse was not detected.
There were no differences in LOS in PICU (group 1, 3 days (IQR 2–5) and group 2, 3 days
(IQR 2–6), with p = 0.120) and LOS in hospital (group 1, 7 days (IQR 6–9), group 2, 7 days
Fig 3. Representation of the evolution of procalcitonin (PCT, ng/mL) in infected patients according to the type of microorganism.
Mann-Whitney U test.
https://doi.org/10.1371/journal.pone.0220686.g003
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(IQR 6–10). There were also no statistically significant differences when the LOS was analysed
only in patients with suspicion of infection (227): in PICU group 1, 6 days (IQR 3–9) and
group 2, 6 days (IQR 4–12.8), with p = 0.179; and in hospital, group 1, 9 days (IQR 8–15.5)
and group 2, 11 days (IQR 8–21) with p = 0.316. In the multivariate analysis, age under 1 year
(OR 2.786, CI95% 1.181–6.572, p = 0.019) and hours of MV (OR 1.015, CI95% 1.004–1.025,
p = 0.005) were independently associated with a prolonged LOS in PICU (more than 5 days)
in patients with suspicion of infection. The prolonged LOS in the PICU was not related to the
protocol group, the confirmation of infection, the inotropic score at 24 hours, nor to the Aris-
totle score higher than 2, the times of surgery, the need for renal replacement therapy or
ECMO. The reinfection entailed an increase in the number of days in PICU and hospital in
both groups (group 1 the median days in PICU with reinfection was 11 (IQR 7–18.5) and with-
out reinfection, 3 days (IQR 2–5); in group 2, the median days in PICU with reinfection was
16 (IQR 4.5–32) and without reinfection, 3 (IQR 2–5). The LOS in hospital was also larger: in
group 1, the median days in case of reinfection was 23 (IQR 14–34.5) and without reinfection,
7 (IQR 6–9); in group 2, with reinfection the median days was 30 (13–43.5) and without rein-
fection, 7 days (IQR 6–9). p value was<0.001 in all cases.
Discussion
To our knowledge, this is the first study in children in which the implementation of a PCT-
guided protocol for antibiotic stewardship after CVS has been evaluated. Results have shown
an improvement in the antibiotic policy, with a reduction of 8.4% in the utilization of antibiot-
ics and a greater awareness of the need to optimize their use. The decision of stewardship was
similar in the two periods, but the stewardship was 1 day earlier in group 2. Also stewardship
was not applicable to more patients in group 2 because of the optimal empiric treatment that
was initiated. The antibiotic duration was also 1 day less in the PCT-guided group and there
were 2 more antibiotic-free days.
Concern about the policy of antibiotic exposure is high due to the rise in emerging multi-
resistant bacteria. This increase is especially related to the broad-spectrum antibiotic indica-
tion but even the duration of prophylactic antibiotic is important in order to prevent new
resistance [26]. PCT has shown its usefulness in differentiating bacterial infection from inflam-
mation after CVS, which allows avoiding the indication of antibiotics [9,11]. After CVS,
patients may be very unstable, and broad-spectrum antibiotics are commonly started due to
a possible infectious trigger, despite the laboratory results. Therefore, biomarkers could help in
a second step, in order to improve antibiotic stewardship and reduce the duration of the
antibiotics.
Most data on antibiotic stewardship guided by PCT are published about adults, among
whom the rise of multi-resistances is a real and important problem nowadays. One of the first
studies was published in 2010 (PRORATA trial)[16], a multicentre randomised and controlled
trial in adults admitted to an intensive care unit. In this study, the group that followed a proto-
col guided by PCT received 2.7 fewer days of antibiotics than the control group, without
adverse effects. Similar studies were later published [27], and two recent meta-analyses con-
firmed the usefulness of PCT for reducing antibiotic exposure of adults in intensive care units
without an increase in complications [18,28]. However, the authors noted two different types
of pathologies in which the duration of the antibiotic treatment was not modified by the PCT-
guided protocol: abdominal infections and renal impartment [18]. In addition, a recent
Cochrane review concluded that current data do not provide good evidence to support PCT-
guided protocols, possibly due to the lack of homogeneity among the included studies [29]. A
2017 Cochrane review in adults recommended the use of PCT for guiding the cessation of
Procalcitonin to stop antibiotics after cardiovascular surgery in children
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antibiotics in acute respiratory infection because of the reduction in both the number of days
with antibiotics and in mortality [30]. In contrast with these results, a recent study in adults
with suspected low-respiratory tract infection did not yield evidence of a reduction in the use
of antibiotics with a PCT-guided protocol [31]. Probably this was secondary to low adherence
to the protocol and also because a high rate of patients in whom bacterial infection would not
be suspected using clinical signs were included, thereby underestimating the usefulness of
PCT-guided protocols in pathologies with which physicians would use antibiotics more con-
sistently. In surgery patients, some authors have demonstrated the usefulness of PCT guided
protocols, as in peritonitis cases, with a 50% reduction in antibiotic duration [32]. There are
no data in adults about the use of a PCT-guided protocol in patients after CVS.
Data in PICU population are scarce. In newborns with early-onset sepsis, PCT-guided anti-
biotic protocol showed a reduction of 22.4 hours of antibiotics [14]. There was also demon-
strated to be a decrease in the exposure to antibiotics in children with nosocomial infection in
PICU [33] with a reduction of 2 days of antibiotics following a PCT-guided protocol similar to
the one used in our study. No increase in complications or adverse outcomes was detected.
There are no published studies about the use of PCT-guided protocols in children after CVS,
although preliminary published results seem to indicate that the use of PCT could reduce the
exposure to antibiotics in these patients [34].
In the present study, the local antibiotic policy algorithm in these patients was changed due
to the concern of the abuse of antibiotics. Apart from the introduction of the PCT criteria, no
other significant changes were made in the protocol due to the very low impact of multidrug-
resistant bacteria in our unit. Our results shown that there was not an increase in the steward-
ship after the implementation of the PCT-guided protocol. However, there was a trend toward
reduction of the exposure to broad-spectrum antibiotics (1 day less) and also a day less of anti-
biotics, which meant 2 more antibiotic-free days in the PICU and the hospital. These results
can have a great long-term impact, both at the clinical level, helping to reduce multi-resistance,
and at the financial level, by saving antibiotics. One of the concerns about the reduction of the
duration of antibiotic therapy is the upturn in reinfections and relapse. In our data, there was
no variation between cohorts, confirming the safety of the newly implemented strategy. Previ-
ous data of a similar nature also showed no increase in adverse events [14,33,35]. During the
study, our local protocol included the prophylaxis until the remove of the mediastinal drainage
(usually 48 hours, as the previous recommendations of The Society of Thoracic Surgeons
[36]). However, due to concerns about antimicrobial resistances, our current prophylaxis pol-
icy has changed after the end of this study to 24 hours [37].
Our secondary objective was to determine if the new protocol helped to reduce the number
of days in PICU. However it was found an increase of LOS in PICU in the group guided by
PCT. The multivariate analysis did not show that this was due to the new protocol, but factors
such as age under 1 year or hours of MV were probably the factors that conditioned this
increase in LOS.
This study presents some limitations because it is a pilot study. One important limitation is
the single-center design, but on the other hand, a large sample of subjects was included.
Another limitation is the exclusion of the patients from the neonatal intensive care unit. Car-
diovascular surgeries in the neonatal period are more complex than in infants and children.
Newborns usually require higher respiratory and inotropic supports and usually have an
increased risk of infection. However, because these are two different units (PICU and the neo-
natal unit) with different antibiotic policies, patients from the neonatal intensive care unit
were excluded in our analysis. Another important limitation is the fact that group 1 and 2 were
recruited at different time periods, making it more difficult to draw binding conclusions.
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However, results are promising as a preliminary study. In the future, a multicenter study or
even a clinical trial would be interesting in order to confirm the present results.
Conclusions
PCT-guided protocol for stewardship in children after cardiac surgery seems to be safe and
useful to decrease the antibiotic exposure. This protocol could help to reduce the number of
days on broad-spectrum antibiotics and the number of days on antibiotics in total, without
risk of developing complications or adverse effects. Resistance is combatted effectively with an
optimal antibiotic policy. However, more research is needed to extend our knowledge of this
biomarker and its usefulness in this kind of protocol, and pediatric clinical trials would be
useful.
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